Chan Y Pu1, Sarah Rodwin2, Bre Nelson2, Najya Fayyaz2, Nicholas Scott2, Rene J Bouchard2, Adrienne Groman3, Mark Hennon4, Sai Yendamuri4. 1. Pulmonary, Critical Care and Sleep Division, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York. Electronic address: chanyeu@hotmail.com. 2. Nichols School, Buffalo, New York. 3. Department of Biostatistics, Roswell Park Cancer Institute, Buffalo, New York. 4. Department of Thoracic Surgery, Roswell Park Cancer Institute, Buffalo, New York; Department of Surgery, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York.
Abstract
BACKGROUND: In patients with clinical N1 disease, minimally invasive surgery (MIS) has potentially better perioperative outcome compared to open thoracotomy. Additionally, whether adjuvant or neoadjuvant chemotherapy produces the best long-term survival is still debatable. METHODS: We queried The National Cancer Database for patients with clinical N1 NSCLC who underwent surgical resection between 2010 and 2014. Comparison between patients receiving MIS and patients who underwent open thoracotomy was done using an intention-to-treat analysis. Comparison was also done among neoadjuvant, adjuvant chemotherapy, and only surgery. Proportional hazard models were used to evaluate the effects of surgical approach and timing of chemotherapy on overall survival. RESULTS: A total of 1440 and 3942 patients underwent MIS and open thoracotomy respectively. MIS achieved better surgical margins (90.0% versus 88.6%) and shorter length of stay (6.5 ± 6.5 versus 7.3 ± 6.4 d, P ≤ 0.01) compared to open thoracotomy. There were no differences in 30-day and 90-day mortality, nor readmission rates. Neoadjuvant and adjuvant chemotherapy were administered to 13.5% and 57.2% of patients respectively. There was no significant difference in the 5-year overall survival between MIS and open thoracotomy (46% versus 46% P = 0.08). There was significantly better 5-year overall survival in neoadjuvant and adjuvant chemotherapy versus only surgery, but no difference between neoadjuvant and adjuvant chemotherapy (48% versus 47% versus 44%, P < 0.01). CONCLUSIONS: In clinical N1 NSCLC, MIS does not compromise oncological quality or overall survival when compared to open thoracotomy. Overall survival improved in patients treated with chemotherapy but there is no difference when given as neoadjuvant versus adjuvant chemotherapy.
BACKGROUND: In patients with clinical N1 disease, minimally invasive surgery (MIS) has potentially better perioperative outcome compared to open thoracotomy. Additionally, whether adjuvant or neoadjuvant chemotherapy produces the best long-term survival is still debatable. METHODS: We queried The National Cancer Database for patients with clinical N1 NSCLC who underwent surgical resection between 2010 and 2014. Comparison between patients receiving MIS and patients who underwent open thoracotomy was done using an intention-to-treat analysis. Comparison was also done among neoadjuvant, adjuvant chemotherapy, and only surgery. Proportional hazard models were used to evaluate the effects of surgical approach and timing of chemotherapy on overall survival. RESULTS: A total of 1440 and 3942 patients underwent MIS and open thoracotomy respectively. MIS achieved better surgical margins (90.0% versus 88.6%) and shorter length of stay (6.5 ± 6.5 versus 7.3 ± 6.4 d, P ≤ 0.01) compared to open thoracotomy. There were no differences in 30-day and 90-day mortality, nor readmission rates. Neoadjuvant and adjuvant chemotherapy were administered to 13.5% and 57.2% of patients respectively. There was no significant difference in the 5-year overall survival between MIS and open thoracotomy (46% versus 46% P = 0.08). There was significantly better 5-year overall survival in neoadjuvant and adjuvant chemotherapy versus only surgery, but no difference between neoadjuvant and adjuvant chemotherapy (48% versus 47% versus 44%, P < 0.01). CONCLUSIONS: In clinical N1 NSCLC, MIS does not compromise oncological quality or overall survival when compared to open thoracotomy. Overall survival improved in patients treated with chemotherapy but there is no difference when given as neoadjuvant versus adjuvant chemotherapy.
Authors: Jennifer L Wilson; Brian E Louie; Robert J Cerfolio; Bernard J Park; Eric Vallières; Ralph W Aye; Ahmed Abdel-Razek; Ayesha Bryant; Alexander S Farivar Journal: Ann Thorac Surg Date: 2014-04-14 Impact factor: 4.330
Authors: Paul J Speicher; Zachary W Fitch; Brian C Gulack; Chi-Fu J Yang; Betty C Tong; David H Harpole; Thomas A D'Amico; Mark F Berry; Matthew G Hartwig Journal: Ann Thorac Surg Date: 2016-07-29 Impact factor: 4.330
Authors: Calvin S H Ng; John K MacDonald; Sebastien Gilbert; Ali Z Khan; Young T Kim; Brian E Louie; M Blair Marshall; Ricardo S Santos; Marco Scarci; Yaron Shargal; Hiran C Fernando Journal: Innovations (Phila) Date: 2019-04
Authors: Enriqueta Felip; Rafael Rosell; José Antonio Maestre; José Manuel Rodríguez-Paniagua; Teresa Morán; Julio Astudillo; Guillermo Alonso; José Manuel Borro; José Luis González-Larriba; Antonio Torres; Carlos Camps; Ricardo Guijarro; Dolores Isla; Rafael Aguiló; Vicente Alberola; José Padilla; Abel Sánchez-Palencia; José Javier Sánchez; Eduardo Hermosilla; Bartomeu Massuti Journal: J Clin Oncol Date: 2010-06-01 Impact factor: 44.544
Authors: Farhood Farjah; David R Flum; Thomas K Varghese; Rebecca Gaston Symons; Douglas E Wood Journal: Ann Thorac Surg Date: 2009-04 Impact factor: 4.330